Loading...
Loading...
RNAZ| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 100.2K |
| Gross Profit | -100.2K |
| Operating Expense | 4,821.7K |
| Operating I/L | -4,901.1K |
| Other Income/Expense | 70.8K |
| Interest Income | 4.8K |
| Pretax | -4,816.9K |
| Income Tax Expense | -4.8K |
| Net Income/Loss | -4,812.2K |
TransCode Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of drugs and diagnostics for metastatic disease treatment and identification. Their lead therapeutic candidate, TTX-MC138, targets metastatic cancer. The company's preclinical programs include siRNA-based modulators of programmed death-ligand 1 and RNA-binding protein LIN28B. Additionally, they have cancer agnostic programs such as RNA-based agonists of the RIG-I-driven immune response, CRISPR/Cas9-based therapy platform, and mRNA-based cancer vaccines. These products are designed to activate cytotoxic immune responses against tumor cells, positioning the company at the forefront of innovative cancer treatment solutions.
